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1INTRODUCTION
The  HIV  pandemic  has  raised  the  profile  of Cryptococcus neoformans
from obscure yeast to the most important fungal cause of morbidity and death
worldwide. Previously described as a rare cause of meningitis in the tropics, or
in patients with some form of acquired immunodeficiency such as
haematological malignancy or organ transplantation, cryptococcal meningitis is
now a significant public health burden in developing countries.
20% of all AIDS deaths are due to cryptococcal meningitis, making it the
second most common cause of death in HIV infection after tuberculosis1.
Moreover, despite the availability of highly active antiretroviral therapy
(HAART), it continues to pose difficult management questions in the
industrialized world.
Mortality from developed countries, secondary to HIV associated
cryptococcal meningitis is in the range if 10-30% while in the developing
countries the mortality is substantial, around 30-40% because of late
presentation, limited access to antifungal therapy and inability to adequately
monitoring intracranial pressure among many reasons2.
Treatment with flucytosine plus Amphotericin B is recommended in
many reference books and guidelines3, 4.  The addition of flucytosine results in
faster sterilization of the CSF and fewer relapses than with the use of
2Amphotericin B alone. Since, flucytosine is not availability in developing
countries. We forced to use the Amphotricin B as initial drug of choice.
Recommended 2-week induction treatment with Amphotericin B
monotherapy for HIV patients with cryptococcal meningitis in resource-limited
settings may be suboptimal. Extending the therapy to 3 weeks is likely to result
in sterilization of the CSF in a majority of patients5.
Questions remain for physicians regarding the optimal combination of
antifungal agents, duration of treatment, accurate indicators of response to
therapy.
Hence, this study is an attempt to throw light on treatment scenario of
cryptococcal meningitis in HIV sero-positive patients.
3REVIEW OF LITERATURE
Cryptococcal meningitis has emerged as a leading cause of
infectious morbidity and mortality in patients with AIDS. It is the second most
common cause of opportunistic neuro-infection among HIV sero-positive
patients.
CRYPTOCOCCUS
The genus Cryptococcus contains at least 39 species of yeast, but few are
able to cause disease in humans6 (Casadevall & Perfect 1998). Even those that
do cause infection are not primarily pathogens, they have so-called ‘ready-made
virulence’ as a side-effect of their adaptation to their environments.
Most human infections are due to C. neoformans. Disease has very rarely
been attributed to other species such as C. flavescens (formerly laurentii).
C. neoformans is an encapsulated yeast first identified as a human pathogen in
1894 when it was isolated from the tibia of a patient in Germany by Busse and
Buschke7 (Mitchell & Perfect 1995). The same year it was also isolated from
peach juice by Sanfelice8 (Mitchell & Perfect 1995).
The first description of cryptococcal meningitis was published in 1905 by
von Hansemann, although a case of chronic meningitis described in 1861 by
4Zenker, prior to the pathogen isolation, was probably the first case history9, 10
(Mitchell & Perfect 1995; Casadevall & Perfect 1998).
MICROBIOLOGY
Cryptococcus neoformans is dimorphic, existing in the asexual yeast form
characterized by oval to spherical cells with a polysaccharide capsule, and in the
sexual or perfect state characterized by the presence of basidiospores. The
sexual form has not been described in association with clinical specimens and is
observed only during mating and mating has only been observed under
laboratory conditions. The asexual form reproduces through budding, which is
frequently seen in clinical specimens. Some strains produce pseudohyphal
forms that may be seen in tissue sections.
C. neoformans is readily cultured in the laboratory, producing mucoid
colonies within 36–72 h, although growth is inhibited at 37 °C. Colonies are
white to cream in colour, but characteristic dark brown colonies are formed
when grown on birdseed agar. The organism grows readily in automated blood
culture systems.
There are three varietal forms of C. neoformans – C. neoformans var
grubii, C. neoformans var gattii, and C. neoformans var neoformans.  They are
distinguishable by serotyping using rabbit antisera, and by DNA fingerprinting
techniques such as amplified fragment length polymorphism analysis11, 12
5(Boekhout et al. 1997; Boekhout et al. 2001). The different varietal forms are
now thought to represent different species13 (Franzot et al. 1999). They have
different environmental niches, geographical distributions, and affect  different
patient groups (Table 1).
Table 1. varietal forms of Cryptococcal neoformans
PATHOGEN SER
OTY
PE
GEOGRAPHIC
DISTRIBUTION
ENVIRONMENTAL
ASSOCIATION
AFFECTED
PATIENT
GROUPS
C.
neoformans
var grubii
A Worldwide Birds, particularly
pigeon excreta
HIV patients
(98% of all
isolates),
Immuno-
suppressed
patients
Rarely
immune-
competent
C.
neoformans
var gattii
B,C Tropic and
subtropics
Flowering
eucalyptus trees
Immuno-
competent
patients
C.
neoformans
var
neoformans
D World wide Birds, particularly
pigeon excreta
Immune
suppressant and
rarely immune-
competent
C.
neoformans
var
grubii/var
neoformans
hybrid
A,D Not known Not known Rare clinical
isolates
immuno-
suppressed
6The vast majority of infections world-wide occur in HIV patients and are
due to serotype A (C. neoformans var grubii). In the absence of serotyping, var
gattii can be distinguished from var neoformans and var grubii through growth
on canavanine glycine-bromothymol blue agar.
C. neoformans var grubii and C.neoformans var neoformans Both
these varieties predominantly affect the immunosuppressed, and var grubii
(serotype A) is responsible for the vast majority of infections in HIV-positive
patients. Their ecological niche is not well defined, but C. neoformans is not
primarily a pathogen. It is associated with pigeon droppings and soil. Birds are
not thought to develop disease because of their relatively high body
temperature, which inhibits the growth of Cryptococcus.
C. neoformans var gattii This variety occurs in the tropics and subtropics
and is found in association with flowering eucalyptus trees such as the red river
gum (Eucalyptus camaldulensis) (Ellis & Pfeiffer 1990). Disease predominantly
occurs in immunocompetent patients and there is a strong male preponderance
(Chen et al. 2000). Interestingly, there has recently been an outbreak of this
infection on Vancouver Island, British Columbia, where the climate is far from
subtropical.
7Mammals other than humans are susceptible to infection with this
organism and, perhaps unsurprisingly, infection in koala bears is well
documented. However, disease has also been recorded in dolphins in the
Vancouver Island outbreak.
SPECTRUM OF DISEASE
While meningitis is by far the most common manifestation of
cryptococcal infection, other infectious syndromes are well recognized. They
will  be  described  briefly  below,  but  the  focus  of  this  study  will  be  on
meningitis. Infection is believed to occur through inhalation and the primary site
of infection is the lung. It is likely that most such infection is asymptomatic.
Primary infection may result in either immediate pulmonary or disseminated
disease, or it may be quiescent for many years, with subsequent disease
development following an immunosuppressive event later in life. Many of the
early case reports were of patients with cancer. Disease has been described in
almost  all  body  systems   –  the  first  case  report  was  of  osteomyelitis,  but  the
brain remains the organ with a particular vulnerability to infection for reasons
that are not well understood.
CENTRAL NERVOUS SYSTEM
Meningitis is the most common manifestation of cryptococcal infection.
It would be more accurate to describe the syndrome as a meningoencephalitis,
8since histopathological examination demonstrates that along with the
subarachnoid space the brain parenchyma itself is usually involved (Lee et al.
1996). Presentation varies, and the diagnosis should be considered in all cases
of subacute meningitis (presentation over 2–4 weeks). However, the organism
can also cause an acute meningitis occurring over a few days to a week, and a
true chronic meningitis, the longest duration of illness recorded being 29
years(Casadevall & Perfect 1998). Other neurological presentations include
focal  signs  secondary  to  cryptococcoma  development,  as  well  as  subdural
effusions and spinal cord lesions secondary to granuloma. It is important to
remember that as well as causing meningitis, cryptococcal infection is one of
the causes of reversible subacute dementia (perhaps because of the
hydrocephalus although yeasts are found in brain parenchyma), and the
diagnosis should be excluded in those patients with a relevant exposure history,
such as travel to the tropics, or risk of immunosuppression. Endophthalmitis can
occur alone or as part of meningitis. Blindness is a common sequelae of
infection, particularly in Viet Nam in apparently immunocompetent patients.
Lung
The lung is the second most common organ to develop clinical disease
usually pneumonia, which can occur in the immunocompetent, particularly with
var gattii infection. Other pulmonary manifestations include solitary nodules,
superior vena cava obstruction, cavitation and pleural effusions/empyema – the
9radiographic appearances can be very similar to pulmonary tuberculosis. HIV
patients who are infected with C. neoformans tend to present with meningitis
rather  than  pulmonary  disease.  Although  up  to  one-third  of  them  have  an
abnormal chest Xray, pulmonary symptoms are rare (Casadevall & Perfect
1998). Var gattii much more commonly causes pulmonary disease (without
meningitis) in immunocompetent patients, resembling pulmonary TB. It is
extremely unusual for HIV patients to get symptomatic pulmonary disease due
to cryptococcal infection.
Skin
The skin is the third most common organ to be affected by cryptococcal
infection. Infected skin lesions can have a wide variety of appearances,from
papules through to plaques, subcutaneous swellings, sinuses and blisters.Skin
involvement appears to be becoming more common with HIV infection and the
lesions often resemble molluscum contagiosum. In fact, other skin diseases may
coexist within the same lesion (for example Kaposi’s sarcoma). While skin
infection can occur following inoculation, for example through needle stick
injury, it is generally the result of disseminated cryptococcal infection and so
other sites of potential infection such as brain, heart and lungs should be
investigated.
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EPIDEMIOLOGY OF CRYPTOCOCCAL MENINGITIS
Cryptococcosis is a rare infection in healthy human populations.
Therefore the prevalence of cryptococcal disease in a population can be
considered as an indicator of the degree of immune suppression in that group.
Indeed, cryptococcal meningitis is a sentinel for the spread of the HIV
pandemic. In common with many hospitals in Asian countries, the Hospital for
Tropical Diseases in Ho Chi Minh City has seen a large rise in the number of
clinical isolates of C.neoformans over recent years that represents the spread of
HIV within our community.
The HIV pandemic has lead to a massive increase in the number of cases
of cryptococcal meningitis. Generally, there appears to be a preponderance of
males affected, even after adjusting for sex differences in HIV infection, and
most cases occur in the 20–50 years old age group (Lewis & Rabinovich 1972).
Cryptococcosis is rare in children. Conditions other than HIV that predisposeto
infection include:
• immunosuppressive therapy associated with organ transplantation;
• sarcoidosis;
• lymphoproliferative disorder;
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• hypogammaglobulinaemia;
• corticosteroid therapy;
• systemic lupus erythematosus;
• cirrhosis;
• peritoneal dialysis (Casadevall & Perfect 1998).
The effect of diabetes mellitus on predisposition to cryptococcal
meningitis is unclear. Apparently normal patients who develop invasive
cryptococcal disease due to serotypes A or D may have some underlying
unidentified subtle immune defect (Schimpff & Bennett 1975). However,
invasive cryptococcosis due to serotypes A or D probably does occur in
otherwise normal individuals, and the incidence is estimated at 0.2 per million
people per year (Friedman 1983).
THE HIV PANDEMIC
The  HIV  pandemic  has  such  a  profound  impact  on  the  prevalence  of
cryptococcal disease that it is important to understand its scale. Currently there
are 40 million people living with HIV/ AIDS (UNAIDS/WHO 2003). The vast
majority (27 million) of these are in sub-Saharan Africa where the overall
seroprevalence is 7.5–8.5% of 15–49 years old but this rises to 45% in some
countries. There are 6 million people living with HIV in south and south-east
12
Asia. In 2003 there were 3 million HIV deaths and 5 million new infections
worldwide. The epidemic continues to grow rapidly, particularly in south and
south-east Asia (up to 1.1 million new infections in 2003) and Russia. Recently
it was estimated that in Botswana, where HIV seroprevalence approaches 45%,
9 out of 10 of the current 15- year-old boys will die from HIV infection. In Ho
Chi Minh City, Viet Nam, more than 80% of intravenous drug users were HIV
positive by the end of 2001.
HIV infection leads to a progressive inexorable fall in CD4 count. A CD4
count of less than 100 cells/?L (normal range 500–1500 cells/?L) dramatically
increases the risk of cryptococcal meningitis. In much of the developing world
lack of access to HIV testing and health education means that many patients
have CD4 counts substantially lower than this when they present to health
services, and so they are already severely immunosuppressed. It should be
remembered that absolute CD4 counts should only be taken as a guide to help
generate differential diagnoses – individual patients can lose disease-specific
immune responses yet have relatively well-preserved CD4 counts, and therefore
be at risk of opportunistic infections. While Highly Active Anti-Retroviral
Therapy (HAART) is effective in producing meaningful immune reconstitution,
it is unavailable to the vast majority of people infected with HIV due to cost and
lack of political will. Thus there will be a large rise in the incidence of
tuberculosis and opportunistic infections as the pandemic progresses. For
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example, in parts of Africa up to 90% of adult in-patients on general medical
wards are HIV positive, and in Zimbabwe 45% of all meningitis is caused by
Cryptococcus neoformans (Mwaba et al. 2001).
CLINICAL PRESENTATION OF CRYPTOCOCCAL
MENINGITS
The presentation varies. The most frequent symptom in both the
immunosuppressed and immunocompetent is headache, occurring in more than
75% of patients. Fever is also common, occurring in more than half of all cases.
The duration of symptoms before presentation is likely to be longer in
non-AIDS patients,  with  a  history  of  more  than  2  weeks  in  only  25% of  HIV
positive patients. Other common symptoms include nausea and vomiting,
lethargy, personality change, memory loss, stupor and coma (Casadevall &
Perfect 1998). Neck rigidity seems to be uncommon in HIV patients, occurring
in approximately 25%, and focal neurological signs appear in 20% (Friedmann
et al. 1995).
Some African series have reported a higher prevalence of neck stiffness
(Moosa & Coovadia 1997). Skin lesions are reported in between 3 and 10% of
HIV infected patients. In general, focal neurological signs, neurological
sequelae and lung involvement are more common in vargattii infections than in
var grubii or var neoformans infections (Casadevall & Perfect 1998).
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CSF EXAMINATION
Definitive diagnosis of cryptococcal meningitis requires lumbar puncture
with demonstration of yeasts with India ink stain, positive cryptococcal antigen
testing  or  culture  of  the  organism.  CSF  examination  generally  reveals  a  mild
mononuclear leucocytosis (50–500 cells/?L). The CSF protein is rarely greater
than 500–1000 mg/Dl and it may be normal, especially in HIV patients.
In HIV patients, the cell count is usually much lower, and often in single
figures. CSF glucose/ blood glucose is usually slightly low. One study from
Africa found that 17% of AIDS patients with cryptococcal meningitis had
normal CSF parameters (Moosa & Coovadia 1997). Clues to HIV infection on
routine blood testing include mild anaemia, lymphopenia, thrombocytopenia
and raised total protein.
IMAGING
CT brain scan is normal in 50% of patients with cryptococcal meningitis.
There are no pathognomonic findings, and the changes may closely resemble
those seen in tuberculous meningitis.
The most common abnormal finding is hydrocephalus. Magnetic
resonance imaging is more likely to demonstrate abnormalities than CT
scanning. The appearances may differ depending on the cause of any underlying
immunosuppression. For example, in AIDS patients there may be diffuse
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cortical atrophy, and hydrocephalus is reportedly less common. Cortical atrophy
in HIV patients may be a direct consequence of the retroviral infection.
Conversely, gyral enhancement is often seen in HIV negative patients.
Occasionally focal abnormalities representing cryptococcomas will be seen.
Brain imaging is justified to exclude mass lesions and, in the HIV population,
other pathology such as toxoplasmosis or CNS lymphoma. The role of serial
scans in monitoring response to treatment is unclear (Casadevall & Perfect
1998).
MRI scan of the brain  with cryptococcal meningitis (a) compared with MRI scan of a
patient with tuberculous meningitis (b) showing prominent dilated ventricles with
periventricular high signal.
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DIAGNOSTIC TECHNIQUES
India ink test
The CSF India ink test is a simple and relatively sensitive test that
enables the rapid diagnosis of cryptococcal meningitis. Its low cost makes it
suitable for resource-poor settings. A drop of CSF is placed on a slide and
mixed with a drop of India ink. A cover slip is placed on the slide, which is
examined under an oil immersion lens. Yeast cells are easily identified through
the halo effect that occurs around them because of the glucuronoxylomannan
capsule (Fig. 4). The sensitivity of the test rises to 75% with centrifugation of
the clinical sample. However, a concentration of yeasts less than 104 colony
forming units (CFU) is unlikely to be detected, and therefore all patients should
have CSF fungal culture and cryptococcal antigen testing if resources allow. It
is important to note varied that tuberculous meningitis may occur at the same
time as cryptococcal meningitis in AIDS patients, and therefore all patients
should have a CSF smear examined for acid and alcohol fast bacilli to exclude
TB.
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Fig-1 India ink stain of CSF demonstrating many yeast cells of C.Neoformans with prominent
capsule.
Culture
C. neoformans from CSF or blood grows readily on blood or Sabouraud’s
agar at 35 °C. Identification can be confirmed through the demonstration of
capsule growth on corn meal agar, development of characteristic brown mucoid
colonies on birdseed agar, and through commercially available sugar
assimilation test kits.
Biotyping, to distinguish var gattii from var neoformans and var grubii,
can be done relatively cheaply using canavanine-glycine-bromothymol blue
agar, although currently this has little clinical relevance. C. neoformans grows
easily in commercially available automated blood culture systems. Culture of
CSF is more sensitive in detecting cryptococcal infection than the India ink test,
18
with a sensitivity approaching 90%. Positive culture is more likely with larger
volumes of CSF.
Figure  2 (a) Brown mucoid colonies of C. neoformans on birdseed agar and (b) blue
discoloration of CGB agar by C. neoformans var gattii
Cryptococcal antigen
Cryptococcal antigen testing is both sensitive and specifi c in identifying
patients with cryptococcal disease. Several commercial kits are available,
relying on either latex agglutination
or ELISA methodologies. The kits can be used on serum or CSF and the
sensitivity in CSF is greater than 90% in cryptococcal meningitis.
Their sensitivity with blood testing has probably been overstated. The kits
have been designed primarily as qualitative diagnostic tests rather than as tools
to  quantify  the  amount  of  antigen  present.  However,  they  can  be  adapted  to
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offer semiquantitative information and there has been interest in using the tests
to assess individual patient response to treatment. However it is difficult to
ensure  consistency  between  different  patient  samples,  or  over  time  with  the
same patient, and quantitative cryptococcal antigen measurement has so far
proved disappointing as a clinical tool to measure response to treatment (Aberg
et al. 2000).
Serotyping
There are immunotyping kits to distinguish the various cryptococcal
serotypes. However, they are expensive, and currently patient management is
more likely to be altered through knowledge of their underlying immune status.
Distinction between vargattii and other varieties can be satisfactorily
determined using biotyping agar.
20
TREATMENT
Anti-fungal drug options for cryptococcal disease are limited.
Amphotericin B is the mainstay of treatment.
This broad spectrum drug is fungicidal and in vitro resistance is
extremely rare. However, nephrotoxicity is a significant problem, although is
usually reversible if the total dose does not exceed 4 g (Khoo et al. 1994). It is
exacerbated by salt depletion, and it has been suggested that patients should
receive a normal saline infusion prior to amphotericin administration.
Bioavailablity is  extremely  poor  via  the  oral  route  and  it must be given
intravenously. It has curious and poorly understood pharmacokinetics – despite
being undetectable in CSF it is effective in cryptococcal meningitis.
Amphotericin B causes membrane disruption through binding to sterols in the
cell membrane, but it probably also has an effect through stimulating
macrophage function. It can be given intrathecally, but this is recommended
only as part  of  salvage therapy for relapsed patients. The lipid formulations of
amphotericin B have the advantage of lower toxicities, and can be given in
higher dosage of up to 10 mg/kg/day. However, they are considerably more
expensive.
Flucytosine is a nucleotide analogue. Available in oral and intravenous
formulations, it appears to have a synergistic action with amphotericin in vitro
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(Schwarz et al. 2003). A randomised trial showed a trend towards more rapid
CSF sterilization in patients receiving flucytosine in combination with
amphotericin compared with amphotericin alone (van derHorst et al. 1997).
Flucytosine is converted to fluoro-uracil within the fungal cell, and this is the
active drug. It has the disadvantages of high cost, poor tolerability, rapid
development of resistance if used as monotherapy, and the need to monitor
blood levels.
The azole drugs (e.g.fluconazole) have revolutionized the treatment of
fungal infections because of their potency, tolerability, good CSF penetration,
and oral and intravenous formulations.Their mechanism of action is inhibition
of sterol synthesis by the fungal cell so they may in theory adversely affect the
action of amphotericin if used in combination. This has not been born out in
animal studies, and there is now good data emerging from the treatment of
systemic candidaemia that this is unlikely to be a problem (Rex et al. 2003).
There is most experience with fluconazole in the treatment of cryptococcal
meningitis. While it is not as potent as itraconazole in vitro, it has better CSF
penetration and appears more effective in clinical trials (Saag et al 1999). The
newer azoles such as voriconazole and posaconazole appear to have better in
vitro activity against C. neoformans than fluconazole, but there are no data from
controlled trials in cryptococcal meningitis.
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Unfortunately the newer classes of antifungal agents such as caspofungin
do not appear to have good activity against C. neoformans.
CURRENT TREATMENT GUIDELINES
Treatment guidelines were published for cryptococcal meningitis in 2000
(Saag et al. 2000). There are three phases – induction, consolidation and
maintenance (also known as secondary prophylaxis). The guidelines A are
largely  based   upon  conclusions  drawn  from  a  double  blind  multicentre  trial
published in 1997 (van der Horst et al. 1997). This trial compared amphotericin
alone vs. amphotericin combined with flucytosine for the initial 2 weeks of
treatment, followed by either fluconazole or itraconazole for 8 weeks. It was not
analysed on an intention-to-treat basis and a large number of patients appear to
have been lost to follow up. The trial did not show any difference in clinical
outcome between the treatment arms. Despite this, the study investigators
recommended that amphotericin in combination with flucytosine be the first line
treatment for cryptococcal meningitis. While there was a trend towards more
rapid CSF sterilization in the combination treatment arm, and there is some in
vitro evidence from other trials suggesting synergy between amphotericin and
flucytosine,in fact the results from this trial were not robust enough to allow the
investigators to make this recommendation. There is some evidence that in HIV
negative patients the combination of flucytosine with amphotericin is beneficial,
but these data relate to a much lower dose of amphotericin (0.3–0.4 mg/kg/day)
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(Bennett et al 1979). There is no evidence that the combination of flucytosine
with higher dose amphotericin is beneficial. Moreover, HIV positive patients
are more likely to have adverse drug reactions with most of the antifungal drugs
than HIV negative patients. There need to be more treatment trials in
cryptococcal meningitis, but with the advent of HAART there is decreasing
interest in this disease in industrialized countries.
Atul K Patel et al 2010 found that the recommended 2 weeks induction
treatment with Amphotericin B monotherapy for HIV patients with
cryptococcal meningitis in resource-limited settings may be suboptimal for at
least one-third of the patients. Extending the therapy to 3 weeks is likely to
result in sterilization of the CSF in a majority of these patients. This finding
requires confirmation by a larger sample size in appropriately powered studies.
Delaying ART initiation by at least 2 weeks after amphotericin B treatment may
decrease the incidence of IRIS.
Once the first two phases of treatment have been completed, patients with
HIV infection need to continue on long-term fluconazole maintenance therapy.
The dose is 200 mg per day. The relapse rate with this regime is in the order of
2% per year. An alternative maintenance therapy is intermittent amphotericin,
but this is less effective (Powderley 1992). There is increasing evidence that the
rise in CD4 count observed with HAART provides meaningful anti-
24
cryptococcal immune reconstitution, and that it is probably safe to stop
maintenance therapy once the CD4 count has risen above 100 cells/?L
(Vibhagool et al. 2003). However, if the CD4 count falls below 100 cells/?L
again, then most physicians would recommend the reintroduction of
maintenance therapy.
There are less recent data regarding the optimal treatment of cryptococcal
meningitis in non-HIV infected patients. In part this is due to the difficulty in
gathering enough patients to perform adequately powered trials. It is not clear
whether treatment should differ according to the infecting variety of
Cryptococcus. Thus treatment recommendations tend to follow those for HIV
positive patients. An alternative is to give amphotericin B 1 mg/kg/day for 6–10
weeks  but this has the disadvantage of its inconvenient formulation and
nephrotoxicity. If the patients are immunosuppressed they may need to continue
maintenance treatment life-long. Wihout maintenance therapy there is a
significant risk of disease relapse of 15–20%, and therefore close follow-up is
mandatory.
Other than the clinical status of the patient and CSF sterilization, there are
no satisfactory  markers of response to treatment. The difficulties in the use of
cryptococcal antigen titres have been described above. The interpretation of
antigen levels in CSF is further complicated by the fact that the level is a
function of the rate of production and removal. Antigen may be present in brain
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parenchyma and leach into the CSF over some weeks. In HIV-negative patients,
persistently high CSF cryptococcal antigen titres are predictive of relapse, but
there are no precisely defined titre levels to help guide management decisions.
In HIV-positive patients a rise in CSF cryptococcal antigen appears to predict
relapse, but is otherwise of little use. Frequent clinical review and CSF
examination is recommended.
COMPLICATIONS OF CRYPTOCOCCAL
MENINGITIS
Raised intracranial pressure
The commonest complication is raised intracranial pressure (ICP) which
occurs in more than 50% of patients (Saag et al. 2000). This is probably due to
impaired drainage of CSF by polysaccharide capsule. Among HIV-positive
patients,  a  rise  in  ICP over  the  first  2  weeks  of  treatment  is  associated  with  a
poor clinical response. Careful management of raised ICP is thought to reduce
mortality. Current recommendations suggest that this is achieved through
physical drainage of CSF, with repeated lumbar puncture, insertion of drains or
ventriculo-peritoneal shunting but there have been no large-scale randomized
trials of the impact of these interventions. It is not clear how frequently lumbar
puncture should be performed for therapeutic drainage. The current
recommendations are that lumbar puncture should be performed daily to keep
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the CSF pressure within the normal range in those patients who have an ICP >
200 mm CSF until the pressure has been normal for several days. Mannitol has
not been found to be useful in managing raised ICP. Published guidelines
suggest that corticosteroids should be avoided in HIV-positive patients because
of their high fungal burden and the potential for further immunosuppression.
However, there are no data to confirm these recommendations.
There has also been interest in the use of acetazolamide as a treatment for
raised ICP. The most recent controlled trial in HIV patients was stopped
because of adverse events, including acidosis, in the active drug arm (Newton et
al 2002). However, only a small number of patients had been recruited, and the
trial needs to be repeated. It may be that the dose of acetazolamide at 1 g/day
was too high.
Visual impairment
Blindness is common in cryptococcal meningitis, particularly in HIV-
negative patients (Seaton et al. 1997b). It is thought to be due to raised
intracranial pressure, direct invasion of the optic nerve, or adhesive
arachnoiditis. There are some retrospective data that suggest that corticosteroids
may be beneficial in HIV-negative patients with var gattii infections in reducing
visual morbidity (Seaton et al. 1997a). The current treatment guidelines do not
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recommend their use, but there have been recent trials in bacterial meningitis
demonstrating their good safety profile, and a prospective trial is needed.
Cerebral infarction
Cerebral infarction is a recognized event in chronic meningitides such as
tuberculous meningitis, and it is also recognized in cryptococcal meningitis
(Lan et al. 2001). There is evidence from the murine model of cryptococcal
meningitis that the anti-infammatory fibrinolytic agent pentoxifylline reduces
mortality when used in combination with amphotericin B (Ostrosky- Zeichner et
al. 1996). There are no data on the use of anti-infl ammatory drugs in humans
with cryptococcosis.
IMMUNE RECONSTITUTION IN HIV
RELATED DISEASE
Over the past few years it has been recognized that patients with HIV can
develop clinical syndromes, analogous to the paradoxical reactions seen during
the treatment of tuberculosis, as they develop immune reconstitution as a result
of starting HAART. A small number of cases of apparent immune reconstitution
occurring in patients recently treated for cryptococcal meningitis have now been
described (Jenny-Avital & Abadi 2002). The cases are usually sterile
meningitides, and occurred up to 11 months after initiation of HAART. The
clinical difficulty is indistinguishing relapsed disease from the reconstitution
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syndrome. Consequently the patients were managed with antifungal treatment
and continuation of HAART. As for most opportunistic infections, it is not yet
clear whether it is better to begin antiretroviral therapy immediately, or to delay
until the course of antifungal therapy is established or completed.
PROGNOSIS AND OUTCOME
Cryptococcal meningitis is universally fatal if untreated. With treatment,
survival is much improved but the death rate remains significant,with the trials
reporting mortality rates of between 5.5 and 46% (Casadevall & Perfect 1998).
Drug toxicities are frequent, occurring in up to 60% of patients. The
patient’s underlying disease is probably the single most important factor
determining eventual outcome. Those with malignancy have a poorer prognosis
than AIDS patients in industrialized countries because of their older age and the
relative difficulty in controlling their underlying disease. There has been
inconsistency in the factors identified as poor prognostic indicators, but those
thought most likely to predict treatment failure are a high initial CSF opening
pressure, high CSF cryptococcal antigen and abnormal mental status at
presentation (Casadevall & Perfect 1998).
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AIM AND OBJECTIVES
Aim:
To compare the efficacy of 3 weeks Amphotericin therapy vs 2 weeks
Amphotericin therapy in HIV positive cryptococcal meningitis patients  & also
ascertain the impact of both on CSF parameters.
Objectives:
?  To diagnose the Cyptococcal meningitis by detection of  Cryptococcal
antigen in CSF,india ink preparation and culture.
? To treat the Cryptococcal meningitis proven HIV positive patient with 3
weeks Amphotericin regimen
? To compare the impact of Amphotericin therapy at the end of  second
week and third week by repeating  india ink preparation,culture  and
other  CSF parameters.
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MATERIALS AND METHODS
Prospective observational study; sample size: 100
Inclusion criteria:
? Age ? 18 yrs
? Both the genders
? Patient/relative willing to give informed consent
? Clinically suspected case of meningitis
? Global cerebral syndrome with proven case of Cryptococcal meningitis
Exclusion criteria:
? Already treated or under the treatment for cryptococcal meningitis
? Any contraindication for performing lumbar puncture
? Partially treated & relapsing cases
? Patient /relative not willing to give informed consent
? Age <18 & >60 years
Methodology:
      After the initial case history and detailed examination all HIV reactive
individuals suspected of having meningitis/ meningoencephalitis are to be
subjected to CSF analysis (including India ink preparation, culture and
antigen detection) ,CD4 counts and imaging studies. The positive cases
have to be followed up with repeat CSF analysis at 2nd and 3rd week after
a regimen of anti fungal therapy. So, by comparing the CSF parameters
vise; India ink preparation, culture, cell counts, protein, sugar at the end
of 2nd and 3rd week after Amphotericin treatment, the efficacy of duration
of treatment and outcome can be ascertained.
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OBSERVATION AND RESULTS
INCIDENCE OF CRYPTOCOCCAL MENINGITIS IN 100 HIV
PATIENTS
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TABLE 1
AGE
SAMPLE AGE IN YEARS
MEAN SD
CRYPTOCOCCAL NEGATIVE
PATIENTS (n=74)
36.2 5.2
CRYPTOCOCCAL POSITIVE PATIENTS
(n=26)
34.5 5.0
In our study population, mean age of patients with cryptococcal meningitis
were 34.5, whereas in cryptococcal negative HIV patients it was 36.5 years.
TABLE-2
SEX
SEX CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
MALE 55 19 74
FEMALE 19 7 26
In total no of HIV patients there are about 75% were male and about 25% were
female, in cryptococcal meningitis group 73% were males and 27% were
females.
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TABLE-3
MARITAL STATUS
MARITAL STATUS CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
MARRIED 64 25 89
UNMARRIED 10 1 11
In total no of HIV patients there are about 90% were married and about 10%
were unmarried, in cryptococcal meningitis group 96% were married and 4%
were unmarried.
TABLE-4
EDUCATIONAL STATUS
EDUCATION CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
UNEDUCATED 7 3 10
PRIMARY 45 15 60
SECONDARY 14 5 19
DEGREE 8 3 11
Most number of patients completed only their primary level of education in
both groups.
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TABLE-5
PROMISCOUS SEX
PROMISCOUS SEX CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
YES 6 2 8
NO 68 24 92
Ninety two percent of total HIV patients not maintained their sexual
promiscuous like that patients with cryptococcal meningitis not maintained
their sexual promiscuous.
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TABLE-6
OCCUPATION
OCCUPATION CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
UNEMPLOYED 9 3 12
LABOUR 33 7 40
FARMER 8 2 10
PRIVATE 8 2 10
PROFESSIONAL 3 3 6
HOUSEWIFE 2 0 2
DRIVER 11 9 20
From the above table most number of HIV positive cryptococcal negative
patients was engaged in labor works, whereas in patients with cryptococcal
meningitis most of them were drivers.
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TABLE-7
INITIAL CLINICAL PRESENTATION
CLINICAL
PRESENTATION
TOTAL
(n=100)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
FEVER 89 25
HEADACHE 96 24
MALAISE 39 14
VOMITTING 42 10
NECK STIFFNESS 25 10
ALTERED
SENSORIUM
28 8
SEIZURE 14 2
COUGH 4 2
DYSPHAGIA 10 1
FOCAL
NEUROLOGICAL
DEFICITS
16 1
BLURRING OF
VISION
2 1
Headache (96% of patients) is the most common presentation in total no of
HIV patients, whereas fever and headache ( was the most common
presentations in cryptococcal meningitis patients.
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TABLE-8
PRE EXIXSTING DISEASES
PRE EXISTING
DISEASES
CRYPTOCOCCAL
NEGATIVE
PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS
(n=26)
TOTAL
TB 24 4 28
ON ATT 15 2 17
TB was the pre existing disease (28% of patients) in both cryptococcal negative
and positive HIV patients; it was present 4 out of 26 patients with cryptococcal
meningitis, out of total TB patients only 17 of them on ATT.
TABLE-9
DISEASE PATTERN OF HIV REACTIVE INDIVIDUALS SUSPECTED OF HAVING
MENINGITIS/MENINGOENCEPHALITIS
DISEASES TOTAL NO OF
PATIENTS
CRYPTOCOCCAL
MENINGITIS
26
TB MENINGITIS 7
TOXOPLASMOSIS 4
CNS LYMPHOMA 2
In 100 HIV reactive individuals with features suggestive of meningial
involvement, 26 patients were cryptococcal meninigitis, 7 patients had TB
meningitis, 4 patients had Toxoplasmosis and 2 patients had CNS Lymphoma.
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TABLE-10
CD4 COUNT
In our study, mean CD4 level in patients with cryptococcal meningitis was
56.42, and in cryptococcal negative HIV patients it was 76.6, and this difference
in CD4 count was found to be statistically significant (p=0.025)
SAMPLE CD4 COUNT SIGNIFICANCE
MEAN SD
CRYPTOCOCCAL NEGATIVE
PATIENTS (n=74)
76.6 42.27 T=2.2715
P=0.025
SIGNIFICANT
CRYPTOCOCCAL POSITIVE
PATIENTS (n=26)
56.42 27.15
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TABLE-11
INITIAL CSF PARAMETER
INITIAL CSF
PARAMETER
CRYPTOCOCCAL
NEGATIVE PATIENTS
(n=74)
CRYPTOCOCCAL
POSITIVE
PATIENTS (n=26)
SIGNIFICANCE
MEAN SD MEAN SD
CSF PROTEIN 145.7 92.9 150.84 47.3 T=0.2699
P=0.7829
CSF SUGAR 37.9 17.1 15.61 8.7 T=6.321
P=0.000
SIGNIFICANT
CSF CELL COUNT 40.02 62.4 32.30 18.4 T=0.6189
P=0.53
Initial CSF routine characters in both groups were;
? Mean CSF protein was 150.84 and 145.7 in cryptococcal positive
and negative patients respectively,
? Mean sugar value was 15.61 in cryptococcal positive patients and
37.9 in cryptococcal negative patients and this different was found
statistically significant (p=0.0000),
? Mean CSF cell count was 32.3 and 40 in cryptococcal positive and
negative patients respectively.
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TABLE-12
CSF PARAMETER OF SECOND AND THIRD WEEK AFTER AMPHOTERICIN
TREATMENT
CSF PARAMETER SECOND WEEK THIRD WEEK SIGNIFICANCE
MEAN SD MEAN SD
CSF PROTEIN 102.04 29.5 62.6 20.8 T=5.5772
P=0.000
SIGNIFICANT
CSF SUGAR 32.5 11.4 55 10.3 T=7.487
P=0.000
SIGNIFICANT
CSF CELL COUNT 13.9 12 2 4.4 T=4.769
P=0.000
SIGNIFICANT
? Mean CSF protein level at the end of 14th day of Amphotericin B
treatment was 102 and it became further reduced to 62.6 after one
week extended Amphotericin B treatment, and this improvement in CSF
protein level was statistically significant (p=0.00).
? Mean CSF sugar level at the end of 14th day of Amphotericin B treatment
was 32.5 and it became further increased to 55 after one week extended
Amphotericin B treatment, and this improvement in CSF sugar level was
statistically significant (p=0.00).
? Mean CSF cell count level at the end of 14th day of Amphotericin B
treatment was 13.9, and it became further reduced to 2 after one week
extended Amphotericin B treatment, and this improvement in CSF cell
count level was statistically significant (p=0.00).
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TABLE-13
INDIA INK AND CULTURE ON SDA
CSF PARAMETER SECOND WEEK THIRD WEEK SIGNIFICANCE
POSITIV
E
NEGATIV
E
POSITIV
E
NEGATIV
E
INDIA INK FOR
CRYPTOCOCCI
22 4 5 21 Chi square=22.26
P=0.000
SIGNIFICANT
CULTURE IN SDA 19 7 3 23 Chi square-17.72
P=0.000
SIGNIFICANT
CSF became sterile on the 14th day of Amphotericin B in 7 patients
(26.9% ) while 19 patients (73.1%) had positive CSF culture, India ink became
negative on the 14th of treatment in 4 patients (15.3%) while had still positive in
22 patients (84.6%), and all these patients were treated with an extended course
of Amphotericin B by one more week.
At the third week about 23 out of 26 patients CSF became sterile, 21 out
of  26 patients shown negative in CSF India ink preparation, these differences
were statistically significant.
42
TABLE-14
CLINICAL IMPROVEMENT OF SECOND AND THIRD WEEK AFTER
AMPHOTERICIN TREATMENT
CLINICAL
IMPROVEMENT
SECOND WEEK THIRD WEEK SIGNIFICANCE
IMPROVED NOT
IMPROVED
IMPROVED NOT
IMPROVED
TOTAL NO OF
PATIENTS
5 21 22 4 Chi square-
22.26
P=0.000
SIGNIFICANT
Only 5 patients (19%) got improved clinically on 14th day of treatment, but after
extension of one more week Amphotericin B treatment 22 patients improved
clinically, 4 patients still not improved even after 3 weeks treatment.
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FIGURE-1
CSF PROTEIN LEVEL 2ND AND 3RD WEEK FOLLOWING
AMPHOTERICIN B TREATMENT
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FIGURE-2
CSF SUGAR LEVEL 2ND AND 3RD WEEK FOLLOWING
AMPHOTERICIN B TREATMENT
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FIGURE-3
CSF CELL COUNT LEVEL 2ND AND 3RD WEEK FOLLOWING
AMPHOTERICIN B TREATMENT
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FIGURE-4
NEGATIVE FOR CRYPTOCOCCI IN INDIA INK AND CULTURE IN SDA AT 2ND AND
3RD WEEK FOLLOWING AMPHOTERICIN TREATMENT
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FIGURE-5
CLINICAL IMPROVEMENT AT 2ND AND 3RD WEEK FOLLOWING
AMPHOTERICIN TREATMENT
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DISCUSSION
In this study,out of the 100 seropositive patients, 26 had cryptococcal
meningitis (26%), 7 had TB meningitis, 4 had toxoplasmosis and 2 had CNS
lymphoma,  The incidence of neurological manifestations in HIV positive
patients according to snider et al was 31% and levy et al was 39%. In India
Gupta et al 41 found an incidence of 25.75% in his study.
AGE
Mean age of the patients in this study were in 36.2 years in seropositive
non cryptococcal meningitis patients, the mean age of the patients with
cryptococcal meningitis were 34.5 years, this is more or less consistent with the
a study in university of California and Sanfransisco where it  was 37.3 years and
38 respectively.
SEX
Male patients were found to have cryptococcal meningitis more common
(73.1%)  as against females (26.9%).  Mehta et al has reported male
predominance with male to female ratio of 12:1. Another study is also
consistent with the finding Patel et al found male female ratio was 8:2.
OCCUPATION
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High incidence of cryptococcal meningitis was noted among
drivers(34%), followed by daily wage labourers with 26%. Perhaps these
patients more
often seek medical help in government hospital and also because HIV infection
rate  are high in this group of patients.
MODE OF TRANSMISSION
Ninety three percent patients with cryptococcal meningitis had
heterosexual behaviour as the risk factor. None of our patients had homosexual
relationship. Gupta et al41 found heterosexual relationship in 64.7%, 5.85% in
drug abusers and blood transfusion in 14.7%.
PRE-EXISTING INFECTION
Among cryptococcal meningitis patients 4 patients (15.4%) had
tuberculosis as pre existing illness. This finding goes accordance with Patel et al
where he found that 22% patients had tuberculosis as pre existing illness.
50
CLINICAL PRESENTATION
FEVER
This was the commonest presentation in cryptococcal meningitis patients
25 out of 26 cryptococcal meningitis patients had suffered from fever.
HEADACHE
This was the commonest presenting symptom in our study. 96 out of the
100 patients suspected to have meningial involvement had headache, 24 out of
26 patients (92.3%) cryptococcal meningitis presented with headache. It is
consistent with Patel et al where 96.3 % cryptococcal meningitis presented with
headache.
ALTERED SENSORIUM
Thirty percent of the cryptococcal meningitis patients had altered
sensorium, whereas in total of 100 HIV patients 28 % of patients had altered
sensorium
Altered sensorium as observed in this study was primarily due to a meningial
infection, cryptococcal meningitis being most frequent, followed by TB
meningitis, Toxoplasmosis and CNS lymphoma. University of California and
Sanfransisco data revealed altered sensorium as a manifestation in secondary
viral infection. Progressive multifocal leucoencephalopathy, toxoplasmosis,
cryptococcosis, HIV dementia and lymphoma.
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SEIZURES
In our study, 14 % of patients had seizure episodes the common cause for
seizures was neurotuberculosis and Toxoplasmosis. Of the 26 patients of
cryptococcal meningitis, 2 patients had seizures (8%). This finding goes against
with Patel et al where 33 % of cryptococcal meningitis patients had seizure.
COMPARATIVE TABLE: 1
Patel et al 2010 This study
No of cryptococcal
meningitis
27 26
Headache 26 (96%) 24 (92%)
Fever 18 (66%) 25 (96%)
Seizure 9 (33%) 2 (7%)
Altered sensorium 9 (33%) 8 (30%)
Focal neurological deficits 4 (14%) 1 (3.8%)
Malaise 10 (37%) 14 (53.8%)
Vomiting 21 (77%) 10 (38%)
Neck stiffness NA 10 (38%)
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SEIZURE DISORDERS
Two patients in this study group presented as seizure disorder (6.8%).
One patient presented with left focal seizure involving upper limb with
secondary generalization and the other patient had generalized tonic clonic
seizures.
Approximately half of HIV infected patients with seizures have no definite
Identifiable disease of the brain and cerebral HIV infection seems to be the most
likely cause of the seizures. It the study by Holtzman et al, HIV encephalopathy
was responsible for seizures in 24% of the patients.
CD4 CORRELATION
There were 26 Patients diagnosed to have Cryptococcal Meningitis. The
mean CD4 count of patients with Cryptococcal Meningitis in the study group
was 56.42 and the mean CD4 count of patients who did not have Cryptococcal
Meningitis was 76.6. Statistically significant different of CD4 count was
observed between the two groups. (P-0.025).
Myoung-don Oh et al (74) detected that CD4+ lymphocyte counts at
presentation were <200/micro L in 27% of the patients with opportunistic
infections
SK Sharma et al (5) found that majority of the patients 82.6% had CD4+
counts <200 cells/?L. 46% had CD4+ counts <50 cells/?L.
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COMPARATIVE TABLE : 2
Gupta et al Bandyopadhyay
et al
Our study
Year of study 1993 2005 2010
Incidence 25% 32.9% 26%
Modes of
transmission
Heterosexual -
64.5%
I.V Drug abuser -
5.85 %
Blood transfusion
-
14.7 %
NA Heterosexual -
100%
Cryptococcal
meningitis
8.8% 6.0% 26%
TB Meningitis 58.82% 12.1% 7%
Toxoplasmosis 3.8% 2.5% 4%
CNS Lymphoma NA NA 2%
54
INITIAL CSF PARAMETER
All patients in our study underwent CSF examinations, India ink
preparation, CSF Crag and CSF culture. Patients presenting with altered
sensorium with focal neurological deficits or intense headache not improving
despite lumbar tape and  negative fungal growth  were subjected to
neuroimaging.
Initial CSF routine characters were;
? Mean CSF protein was 150.84 and 145.7 in cryptococcal positive
and negative patients respectively,
? Mean sugar value was 15.61 in cryptococcal positive patients and
37.9 in cryptococcal negative patients and this different was found
statistically significant (p=0.0000),
? Mean CSF cell count was 32.3 and 40 in cryptococcal positive and
negative patients respectively.
CSF finding in our study is contrast to Kumar et al study where elevated protein
in 45% of patients, CSF sugar low in 75% of patients, CSF WBC count more
than 5 in 55% of patients.
In our study CSF India ink positivity showed in 100% of patients where
in Kumar et al 85% of patients, Crag and culture was positive in all patients
with cryptococcal meningitis in both studies.
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TREATMENT
All cryptococcal meningitis patients (n=26) treated with Amphotericin B
0.7 mg/kg of body wt per day for three weeks used as a induction therapy.
Amphotericin B was infused on 5% dextrose over 8 h and the patient received
500 ml of 0.9% normal saline before infusion to reduce Amphotericin related
toxicity. In addition to these patients were encouraged to ensure liberal intake of
fluids and coconut water and citrus fruit and banana daily. Amphotericin
toxicity was monitored with twice weekly creatinine, BUN and K level.
These patients Ca and Mg levels were also checked and corrected if
required. Amphotericin treatment was discontinued in patients with rising
creatinine level and resumed once creatinine level touches baseline. Fever and
chills related to Amphotericin B infusion were treated with Injection
Hydrocortisone 50 mg iv sos.
Raised intra cranial pressure was controlled with lumbar tape and
mannital.frequency of lumbar tape was guided by patient’s clinical symptoms.
15 to 20 ml of CSF was removed at one time to control the raised ICT.
SUCCESSFUL RESPONSE
Treatment response was defined as sterile CSF culture, India ink
preparation negativity and improved clinically at day 14. Patients with
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persisting positivity in culture, India ink and not improved clinically were
continued for one more week and evaluated with repeat CSF analysis. They
were then consolidated 400 mg of Flucanazole for 8 weeks and maintained on
Flucanazole 200 mg/day.
CSF became sterile on the 14th day of Amphotericin B in 26.9% of the
patients while 73.1% had positive CSF culture, India ink became negative on
the 14th of treatment in 15.3% of patients while had still positive in 84.6% of
patients, mean protein, sugar and cell count on 14th day of treatment were
respectively 102, 32.5 and 13.9, and only 5 patients (19%) got improved
clinically on 14th day of treatment, all these patients were treated with an
extended course of Amphotericin B by one more week.
At the third week about 89% of patients CSF became sterile, 80% of
patients shown negative in CSF India ink preparation, 84.6% of patients
improved clinically, mean protein, sugar, cell count were respectively 62.6, 55,
and 2 at third week following Amphotericin B treatment. These differences
were statistically significant.
In one study done at 2006, CSF became sterile on 12th day of
Amphotericin B in 55.55% of the patients while 33.33% had positive CSF
culture and were treated with an extended course of Amphotericin B by 1 more
week. All these patients became sterile on day 19 ( Kumar et al).
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Hongzhou Lu et al 2005, demonstrated in his study cryptococcal antigen
titre decrease after anti fungal therapy. There was remarkable decrease in
cryptococcal antigen titre after therapy which was significantly related to CSF
leukocyte count, glucose, chloride, fungal smear and fungal culture
measurements. The total protein level in CSF decreases after therapy but this
different was not statistically significant.
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SUMMARY
We carried out a prospective observational study to determine the
treatment response rate, tolerability and outcome of patients with cryptococcal
meningitis in HIV treated with Amphotericin B. Descriptive statistic was used
to analyze the data.
After the initial case history and detailed examination of all HIV reactive
individuals suspected of having meningitis/ meningoencephalitis are to be
subjected to CSF analysis (including India ink preparation, culture and antigen
detection) ,CD4 counts and imaging studies. The positive cases have to be
followed up with repeat CSF analysis at 2nd and 3rd week after a regimen of anti
fungal therapy.  So, by comparing the CSF parameters vise ; India ink
preparation, culture on SDA, cell counts, protein, sugar and clinical
improvement at the end of 2nd and 3rd week after Amphotericin treatment, the
efficacy of duration of treatment and outcome can be ascertained.
A total of 26 patients were diagnosed with cryptococcal meningitis during
the study period. Headache and fever was the most common presenting
symptom of cryptococcal meningitis in HIV-infected patients, followed by
malaise and vomiting. All patients in our study had heterosexual transmission of
disease. Tuberculous meningitis, Toxoplasmosis and CNS lymphoma were the
other opportunistic infection encountered in our study. There was significant
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CD4 count correlation was found between the patients with cryptococcal
meningitis and those without cryptococcal meningitis.
Initial CSF routine characters in both groups were; mean CSF protein was
150.84 and 145.7 in cryptococcal positive and negative patients respectively,
mean sugar value was 15.61 in cryptococcal positive patients and 37.9 in
cryptococcal negative patients and this different was found statistically
significant (p=0.0000), mean CSF cell count was 32.3 and 40 in cryptococcal
positive and negative patients respectively.
Mean CSF protein level at the end of 14th day of Amphotericin B
treatment was 102 and it became further reduced to 62.6 after one week
extended Amphotericin B treatment, and this improvement in CSF protein level
was statistically significant (p=0.00), mean CSF sugar level at the end of 14th
day of Amphotericin B treatment was 32.5 and it became further increased to 55
after one week extended Amphotericin B treatment, and this improvement in
CSF sugar level was statistically significant (p=0.00), mean CSF cell count
level at the end of 14th day of Amphotericin B treatment was 13.9, and it
became further reduced to 2 after one week extended Amphotericin B treatment,
and this improvement in CSF cell count level was statistically significant
(p=0.00).
CSF became sterile on the 14th day of Amphotericin B in 7 patients
(26.9% ) while 19 patients (73.1%) had positive CSF culture, India ink became
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negative on the 14th of treatment in 4 patients (15.3%) while had still positive in
22 patients (84.6%), and all these patients were treated with an extended course
of Amphotericin B by one more week.
At the third week about 23 out of 26 patients CSF became sterile, 21 out
of  26 patients shown negative in CSF India ink preparation, these differences
were statistically significant.
Only 5 patients (19%) got improved clinically on 14th day of treatment,
but after extension of one more week Amphotericin B treatment 22 patients
improved clinically, 4 patients still not improved even after 3 weeks treatment.
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CONCLUSIONS
? Incidence of Cryptococcal meningitis in HIV infection in our study was
26%.
? In our study male out number female in both cryptococcal negative (75%
versus 25%) and positive (96% versus 4%) HIV patients.
? Headache and fever were the two common symptoms observed in this
study.
? Ninety three patients in our study had heterosexual transmission of
disease.
? Tuberculous meningitis, Toxoplasmosis and CNS lymphoma were the
other opportunistic infection encountered in our study.
? Significant CD4 count correlation was found between the patients with
cryptococcal meningitis and those without cryptococcal meningitis.
? We found that the recommended two weeks induction treatment with
Amphotericin B mono therapy for HIV patients with cryptococcal
meningitis in resource limited settings may be sub optimal for at least two
third of patients.
? Extending the therapy to three weeks is likely to results in sterilization of
the CSF in majority of these patients.
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Proforma:
1. Name:
2. Age:
3. Sex:
4. Marital status:
5. Education:
6. Occupation:
7. Address:
8. Height:
9. Weight:
10.HIV detection:
       When detected? :
       Where detected?:
       HAART therapy:
11. Clinical presentation:
12. Antecedent symptoms:
13. Drugs:
14. Liver/lung kidney/heart disease:
15. Hypertension/diabetes/hyperlipidemia:
16. Promiscous sex:
17. Smoking/alcohol:
18. General examination:
19.Vital signs:
20.CNS:
21.CVS
22. RS
23. P/A:
Investigations:
1.urine r/e:
      Albumin
      Sugar
      Deposits
2.RFT:
      Sugar
      Urea
      Creatinine
3.CBC:
4.CXR:
5.ECG:
6.Brain imaging:
7.CD4 count:
8.CSF analysis:
     Appearance:
     Protein:
     Sugar:
     Cell count:
     India ink preparation:
     Culture in SDA:
      Crytococcal antigen:
9.others:
CONSENT FORM
I AGREE TO PARTICIPATE IN THE STUDY TITLED”COMPARATIVE STUDY OF THE EFFICACY OF 3
WEEKS VS 2 WEEKS AMPHOTERICN THERAPY IN HIV POSITIVE CRYPTOCOCCAL MENINGITIS
PATIENTS & ALO ASCERTAIN THE IMPACT OF BOTH ON CSF PARAMETERS”.
I CONFIRM THAT I HAVE BEEN TOLD ABOUT THIS STUDY IN MY MOTHER TONGUE AND HAVE
HAD THE OPPORTUNITY TO ASK QUESTIONS.
I UNDERSTAND THAT MY PARTICIPATION IS VOLUNTARY AND I MAY REFUSE TO PARTICIPATE
AT ANY TIME WITHOUT GIVING ANY REASON AND WITHOUT AFFECTING MY BENEFITS.
I AGREE NOT TO RESTRICT THE USE OF ANY DATA /RESULTS THAT MAY ARISE FROM THE
STUDY.
RELATIVE:
SIGNATURE OF THE RELATIVE INVESTIGATOR
SIGNATURE OF THE PATIENT
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1 42 M 3 6 1 1 3 1 1 1 1 1 2 1 2 1 2 2 2 2 2 2 2 1 0 0 46 1 69 32 40 1 1 1 1 0 1 50 50 2 1 1 2 1 30 60 0 2 2 1
2 36 M 1 3 1 1 1 1 1 1 1 1 1 1 2 0 ATT 2 2 2 2 1 2 1 PT 0 8 1 116 70 0 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3 30 M 1 9 1 1 36 0 1 1 1 1 2 1 2 0 ATT 2 2 2 2 1 2 1 PT 0 9 1 100 38 60 1 1 1 1 0 1 68 25 32 1 2 1 1 58 60 0 2 2 1
4 40 M 0 2 1 1 4 0 1 1 2 2 1 2 2 2 ATT 2 2 2 2 1 2 1 PT 0 114 1 219 74 68 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 40 M 1 3 1 1 8 1 1 2 1 1 2 1 2 0 ATT 2 2 2 2 1 2 1 PT 0 95 1 240 40 24 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 40 M 1 2 1 1 12 2 1 1 2 2 2 2 2 3 ATT 2 2 2 2 1 2 1 PT 0 17 1 50 62 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 36 M 1 2 1 1 6 3 1 1 1 1 2 2 1 0 2 2 2 2 2 2 2 1 0 0 43 1 126 25 42 1 1 1 1 0 1 102 30 20 1 1 2 1 60 65 0 2 2 1
8 35 M 1 2 1 1 3 1 1 1 2 1 1 1 2 0 ATT 2 2 2 2 1 2 1 PT 0 179 1 525 43 120 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 37 M 0 9 1 1 12 12 1 2 2 1 2 2 2 0 ATT 2 2 2 2 1 2 1 PT 0 42 1 114 10 80 1 1 1 1 0 1 130 31 8 1 2 2 1 60 50 0 2 2 1
10 31 M 1 2 1 1 12 12 1 1 2 1 2 1 2 3 0 2 2 2 2 1 2 1 PT 0 69 1 352 16 84 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 29 M 3 4 2 1 36 6 1 2 2 1 2 2 2 0 0 2 2 2 2 2 2 2 0 1 66 1 122 35 18 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
12 41 M 2 2 1 1 120 24 1 1 2 2 2 2 2 3 0 2 2 2 2 2 2 1 0 0 18 1 107 55 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
13 27 M 1 2 2 1 1 1 1 1 2 2 2 2 2 0 ATT 2 2 2 2 1 2 1 0 0 164 1 29 57 20 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
14 35 M 1 9 1 1 12 6 1 1 2 1 2 2 2 0 ATT 2 2 2 2 1 2 1 PT 0 107 1 104 10 8 1 1 1 1 0 1 98 30 4 1 1 2 1 65 60 0 2 2 1
15 33 M 0 2 1 1 12 1 1 1 2 1 2 2 1 4 0 2 2 2 2 2 2 1 PT 0 23 1 148 10 26 1 1 1 1 0 1 60 40 22 1 2 2 1 39 48 0 2 2 1
16 28 M 0 2 1 1 6 2 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 2 0 0 50 1 242 21 72 1 1 1 1 0 1 149 30 50 1 1 2 1 60 65 0 2 2 1
17 30 M 1 9 1 1 10 4 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 60 1 150 25 32 1 1 1 1 0 1 58 25 30 1 2 1 1 45 45 0 2 2 1
18 48 F 1 2 1 1 12 5 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 104 1 123 45 18 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19 42 M 2 3 1 1 36 24 1 2 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 158 32 24 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20 36 M 2 9 1 1 20 12 1 1 2 2 1 1 2 0 0 2 2 2 2 2 2 1 0 0 42 1 256 10 56 1 1 1 1 0 1 180 20 40 1 1 2 1 100 38 16 1 1 2
21 28 M 3 4 2 1 12 0 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 106 1 128 46 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
22 34 M 1 2 1 1 18 10 1 1 1 2 2 1 2 0 0 2 2 2 2 2 2 1 0 0 40 1 190 8 30 1 1 1 1 0 1 100 20 12 1 1 2 1 60 65 0 2 2 1
23 35 M 1 9 1 1 18 6 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 106 40 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
24 40 M 2 4 1 1 10 4 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 104 1 116 40 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
25 45 M 1 2 1 1 8 3 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 96 1 136 30 16 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
26 29 M 3 6 2 1 6 0 1 1 2 2 1 2 2 2 0 2 2 2 2 2 2 1 0 0 86 1 156 10 30 1 1 1 1 0 1 96 26 13 1 1 2 1 60 65 0 2 2 1
27 40 M 1 3 1 1 30 18 1 1 2 2 2 2 1 3 0 2 2 2 2 2 2 1 0 0 56 1 120 30 12 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
28 27 M 2 9 1 1 16 6 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 56 1 106 36 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
29 36 F 1 1 1 1 16 12 1 1 1 2 1 2 2 0 0 2 2 2 2 2 2 2 0 0 100 1 186 10 40 1 1 1 1 0 1 98 26 18 1 1 2 1 48 60 0 2 2 1
30 45 F 1 8 1 1 13 3 1 2 2 2 2 1 1 3 0 2 2 2 2 2 2 2 0 2 50 1 90 40 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
31 38 F 1 1 1 1 18 16 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 88 1 144 12 18 1 1 1 1 0 1 124 16 16 1 1 2 1 100 46 12 1 2 1
32 40 M 0 2 1 1 4 0 1 1 2 2 1 2 2 2 0 2 2 2 2 1 2 1 PT 0 114 1 219 74 68 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
33 42 M 3 6 1 1 3 1 1 1 1 1 2 1 2 1 0 2 2 2 2 2 2 1 0 0 46 1 69 32 40 1 1 1 1 0 1 50 50 2 1 1 2 1 30 60 0 2 2 1
34 36 M 1 2 1 1 12 10 1 2 2 1 2 1 1 3 0 2 2 2 2 2 2 1 0 3 50 1 150 38 28 2 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
35 41 M 2 2 1 1 120 24 1 1 2 2 2 2 2 3 0 2 2 2 2 2 2 1 0 0 18 1 107 55 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
36 27 M 1 2 2 1 1 1 1 1 2 2 2 2 2 0 ATT 2 2 2 2 1 2 1 0 0 164 1 29 57 20 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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37 35 M 1 9 1 1 12 6 1 1 2 1 2 2 2 0 0 2 2 2 2 1 2 1 PT 0 107 1 104 10 8 1 1 1 1 0 1 98 30 4 1 1 2 1 65 60 0 2 2 1
38 32 F 1 2 1 1 10 6 1 1 2 2 1 1 2 0 0 2 2 2 2 2 2 2 0 0 46 1 196 10 30 1 1 1 1 0 1 130 30 20 1 1 2 1 98 36 8 1 1 2
39 50 F 2 4 1 1 24 12 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 24 1 106 10 18 1 1 1 1 0 1 96 40 8 1 2 2 1 60 65 0 2 2 1
40 30 F 1 9 1 1 10 6 1 1 2 2 1 2 2 0 0 2 2 2 2 2 2 1 0 0 40 1 150 10 18 1 1 1 1 0 1 106 36 18 1 1 1 1 50 60 0 2 2 1
41 38 M 2 3 1 1 6 3 2 1 1 2 1 2 2 0 0 2 2 2 2 2 2 1 0 0 66 1 182 19 13 1 1 1 1 0 1 106 20 8 1 1 2 1 70 50 0 2 2 1
42 38 M 2 9 1 1 27 17 2 1 1 1 2 2 2 2 0 2 2 2 2 2 2 1 0 0 98 1 98 36 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
43 39 M 1 2 1 1 60 24 1 1 2 2 2 1 1 3 0 2 2 2 2 2 2 1 0 0 48 1 98 36 6 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
44 44 F 1 1 1 1 24 18 1 1 2 2 2 2 2 2 0 2 2 2 2 2 2 2 0 0 104 1 98 40 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
45 36 M 1 1 1 1 10 1 1 1 2 1 1 2 2 0 0 2 2 2 2 2 2 1 PT 0 60 1 286 30 255 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
46 40 F 1 1 1 1 36 30 1 1 2 1 1 2 1 0 0 2 2 2 2 2 2 2 PT 0 48 1 98 38 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
47 30 M 3 4 2 1 3 0 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 108 1 98 35 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
48 34 M 1 2 1 1 3 0 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 86 24 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
49 41 F 1 1 1 1 24 14 1 1 2 2 2 2 2 0 ATT 2 2 2 2 1 2 2 PT 0 60 1 180 40 250 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
50 45 F 1 8 1 1 13 3 1 2 2 2 2 1 1 3 0 2 2 2 2 2 2 2 0 2 50 1 90 40 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
51 38 F 1 1 1 1 18 16 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 88 1 144 12 18 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
52 40 M 0 2 1 1 4 0 1 1 2 2 1 2 2 2 ATT 2 2 2 2 1 2 1 PT 0 114 1 219 74 68 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
53 42 M 3 6 1 1 3 1 1 1 1 1 2 1 2 1 2 2 2 2 2 2 2 1 0 0 46 1 69 32 40 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
54 36 M 1 2 1 1 12 10 1 2 2 1 2 1 1 3 0 2 2 2 2 2 2 1 0 3 50 1 150 38 28 2 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
55 41 M 2 2 1 1 120 24 1 1 2 2 2 2 2 3 0 2 2 2 2 2 2 1 0 0 18 1 107 55 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
56 27 M 1 2 2 1 1 1 1 1 2 2 2 2 2 0 ATT 2 2 2 2 1 2 1 0 0 164 1 29 57 20 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
57 35 M 1 9 1 1 12 6 1 1 2 1 2 2 2 0 ATT 2 2 2 2 1 2 1 PT 0 107 1 104 10 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
58 32 F 1 2 1 1 10 6 1 1 2 2 1 1 2 0 0 2 2 2 2 2 2 2 0 0 46 1 196 10 30 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
59 50 F 2 4 1 1 24 12 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 24 1 106 10 18 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
60 42 M 3 6 1 1 3 1 1 1 1 1 2 1 2 1 2 2 2 2 2 2 2 1 0 0 46 1 69 32 40 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
61 36 M 1 3 1 1 1 1 1 1 1 1 1 1 2 0 0 2 2 2 2 1 2 1 0 0 8 1 116 70 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
62 30 M 1 9 1 1 36 0 1 1 1 1 2 1 2 0 0 2 2 2 2 1 2 1 PT 0 9 1 100 38 60 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
63 40 M 0 2 1 1 4 0 1 1 2 2 1 2 2 2 0 2 2 2 2 1 2 1 0 0 114 1 219 74 68 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
64 40 M 1 3 1 1 8 1 1 2 1 1 2 1 2 0 0 2 2 2 2 1 2 1 0 0 95 1 240 40 226 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
65 40 M 1 2 1 1 12 2 1 1 2 2 2 2 2 3 ATT 2 2 2 2 1 2 1 PT 0 17 1 50 62 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
66 36 M 1 2 1 1 6 3 1 1 1 1 2 2 1 0 2 2 2 2 2 2 2 1 0 0 43 1 126 25 42 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
67 35 M 1 2 1 1 3 1 1 1 2 1 1 1 2 0 0 2 2 2 2 1 2 1 0 0 179 1 525 43 120 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
68 37 M 0 9 1 1 12 12 1 2 2 1 2 2 2 0 0 2 2 2 2 1 2 1 0 0 42 1 114 10 80 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
69 31 M 1 2 1 1 12 12 1 1 2 1 2 1 2 3 0 2 2 2 2 1 2 1 PT 0 69 1 352 16 84 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
70 29 M 1 2 1 1 0 0 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 2 0 0 66 1 160 10 28 1 1 1 1 0 1 112 20 18 1 1 2 1 98 35 8 1 2 2
71 41 M 2 2 1 1 120 24 1 1 2 2 2 2 2 3 0 2 2 2 2 2 2 1 0 0 18 1 107 55 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
72 27 M 1 2 2 1 1 1 1 1 2 2 2 2 2 0 0 2 2 2 2 1 2 1 0 0 164 1 29 57 20 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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73 35 M 1 9 1 1 12 6 1 1 2 1 2 2 2 0 0 2 2 2 2 1 2 1 0 0 107 1 104 10 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
74 33 M 0 2 1 1 12 1 1 1 2 1 2 2 1 4 0 2 2 2 2 2 2 1 PT 0 23 1 148 10 26 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
75 28 M 0 2 1 1 6 2 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 2 0 0 50 1 242 21 72 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
76 30 M 1 9 1 1 0 1 1 1 2 2 1 2 0 0 2 2 2 2 2 2 1 0 0 60 1 150 25 32 1 1 1 1 0 1 106 30 10 1 1 2 1 45 66 0 2 2 1
77 48 F 1 2 1 1 12 5 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 104 1 123 45 18 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
78 42 M 2 3 1 1 36 24 1 2 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 158 32 24 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
79 36 M 2 9 1 1 20 12 1 1 2 2 1 1 2 0 0 2 2 2 2 2 2 1 0 0 42 1 256 10 56 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
80 28 M 3 4 2 1 12 0 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 106 1 128 46 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
81 34 M 1 2 1 1 18 10 1 1 1 2 2 1 2 0 0 2 2 2 2 2 2 1 0 0 40 1 190 8 30 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
82 35 M 1 9 1 1 18 6 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 106 40 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
83 40 M 2 4 1 1 10 4 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 104 1 116 40 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
84 45 M 1 2 1 1 8 3 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 96 1 136 30 16 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
85 29 M 3 6 2 1 6 0 1 1 2 2 1 2 2 2 0 2 2 2 2 2 2 1 0 0 86 1 156 10 30 2 2 2 2 0 1 96 26 13 1 1 2 1 60 65 0 2 2 1
86 40 M 1 3 1 1 30 18 1 1 2 2 2 2 1 3 0 2 2 2 2 2 2 1 0 3 56 1 120 30 12 2 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
87 27 M 2 9 1 1 16 6 1 1 1 1 2 2 2 0 0 2 2 2 2 2 2 1 0 0 56 1 106 36 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
88 36 F 1 1 1 1 16 12 1 1 1 2 1 2 2 0 0 2 2 2 2 2 2 2 0 0 100 1 186 10 40 1 1 1 1 0 1 98 26 18 1 1 2 1 48 60 0 2 2 1
89 32 F 1 2 1 1 10 6 1 1 2 2 1 1 2 0 0 2 2 2 2 2 2 2 0 0 46 1 196 10 30 1 1 1 1 0 1 130 30 20 1 1 2 1 98 36 8 1 1 2
90 50 F 2 4 1 1 24 12 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 24 1 106 10 18 1 1 1 1 0 1 96 40 8 1 2 2 1 60 65 0 2 2 1
91 30 F 1 9 1 1 10 6 1 1 2 2 1 2 2 0 0 2 2 2 2 2 2 1 0 0 40 1 150 10 18 1 1 1 1 0 1 106 36 18 1 1 1 1 50 60 0 2 2 1
92 38 M 2 3 1 1 6 3 2 1 1 2 1 2 2 0 0 2 2 2 2 2 2 1 0 0 66 1 182 19 13 1 1 1 1 0 1 106 20 8 1 1 2 1 70 50 0 2 2 1
93 38 M 2 9 1 1 27 17 2 1 1 1 2 2 2 2 0 2 2 2 2 2 2 1 0 0 98 1 98 36 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
94 39 M 1 2 1 1 60 24 1 1 2 2 2 1 1 3 0 2 2 2 2 2 2 1 0 3 48 1 98 36 6 2 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
95 44 F 1 1 1 1 24 18 1 1 2 2 2 2 2 2 0 2 2 2 2 2 2 2 0 0 104 1 98 40 13 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
96 36 M 1 1 1 1 10 1 1 1 2 1 1 2 2 0 ATT 2 2 2 2 2 2 1 PT 0 60 1 286 30 255 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
97 40 F 1 1 1 1 36 30 1 1 2 1 1 2 1 0 0 2 2 2 2 2 2 2 0 0 48 1 98 38 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
98 30 M 3 4 2 1 3 0 1 1 2 2 2 2 2 0 0 2 2 2 2 2 2 2 0 0 108 1 98 35 8 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
99 34 M 1 2 1 1 3 0 1 1 1 2 2 2 2 0 0 2 2 2 2 2 2 1 0 0 98 1 86 24 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100 41 F 1 1 1 1 24 14 1 1 2 2 2 2 2 0 ATT 2 2 2 2 1 2 2 PT 0 60 1 180 40 250 2 2 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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